Pembrolizumab Superior to Standard of Care in SCC

December 26th 2018, 9:03pm


A recent trial looked to compare the efficacy and safety of pembrolizumab (Keytruda) with the standard of care for the treatment of head and neck squamous cell carcinoma (SCC).

FDA Grants Accelerated Approval to Pembrolizumab for MCC

December 22nd 2018, 12:38am


Earlier this week, the FDA granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

Soluble CD163 Potential Biomarker in Advanced Cutaneous Melanoma

December 21st 2018, 7:15am


Patients with advanced cutaneous melanoma who are responsive to nivolumab (Opdivo) have higher serum levels of soluble CD163 (sCD163) compared with nonresponders, according to the results of a recent study.

The Allen Institute for Immunology Plans Long-term Goal of Mapping the Immune System

December 15th 2018, 8:00pm


The Allen Institute for Immunology has partnered with several cancer institutions, including the Fred Hutchinson Cancer Research Center, with the primary goal of understanding the differences between a defective and healthy immune system to improve immune-based treatments.

Dr Brian Koffman Explains How PROs Can Provide Insight Into CAR T Benefits

December 12th 2018, 7:40pm


While patient-reported outcomes don’t provide the whole story, they can provide insight into how chimeric antigen receptor (CAR) T-cell therapy changes a patient’s life, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.

Longer-Term JULIET Results Confirm Sustained Response With Tisagenlecleucel in Relapsed/Refractory DLBCL

December 6th 2018, 7:36pm


A median 19-month follow-up of the JULIET trial—a single-arm, open-label, multicenter, global, pivotal phase 2 trial of the chimeric antigen receptor-T cell therapy tisagenlecleucel directed against CD19-expressing B cells—has found a 40% complete response and a manageable safety profile in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Carfilzomib-Based Combination Results in Sustained MRD-Negative Complete Response in Multiple Myeloma

December 6th 2018, 1:40am


Researchers at the 60th American Society of Hematology Annual Meeting & Exposition presented long-term study results showing that high rates of minimal residual disease–negative complete response were sustained with a median duration of over 4 years among treatment-naïve patients with multiple myeloma.

The Value of Novel Immuno-Oncology Treatments

December 4th 2018, 10:00pm


This study assesses the value of novel immuno-oncology treatments to society.

Dr Michael Kolodziej Discusses Concerns Around Paying for Innovative Treatments, Like CAR T

December 3rd 2018, 7:00pm


While new therapies like chimeric antigen receptor (CAR) T-cell therapy, can have amazing results, the innovation of these treatments has outstripped the United States’ ability to pay for them, said Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc.

Real-World Evidence With Axicabtagene Ciloleucel CAR T Treatment Similar to ZUMA-1 Trial Findings

December 2nd 2018, 1:07am


A multicenter retrospective study that evaluated the efficacy and safety of chimeric antigen receptor (CAR) T-cell treatment, axicabtagene ciloleucel (axi-cel; Yescarta), in a real-world setting found a similar response as well as toxicity compared with the ZUMA-1 clinical trial.